Increased Risk of Clopidogrel-Induced Gastric Mucosal Erosion in Elderly Chinese Men Harboring the ABCB1 3435T Allele

References

• Bowman L, Mafham M, et al.; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–1539. doi:10.1056/NEJMoa1804988.30146931
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–1518. doi:10.1056/NEJMoa180581930221597
   PubMed Web of Science ®Google Scholar
• McNeil JJ, Nelson MR, Woods RL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–1528. doi:10.1056/NEJMoa180395530221595
   PubMed Web of Science ®Google Scholar
• Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–1046. doi:10.1016/S0140-6736(18)31924-X30158069
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160–2236. doi:10.1161/STR.000000000000002424788967
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol. 2013;61(8):872–879. doi:10.1016/j.jacc.2012.11.04023333143
   PubMed Web of Science ®Google Scholar
• Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111(12):705–710. doi:10.1016/j.jfma.2011.11.02823265750
   PubMed Web of Science ®Google Scholar
• Mangalpally KK, Kleiman NS. The safety of clopidogrel. Expert Opin Drug Saf. 2011;10(1):85–95. doi:10.1517/14740338.2011.53248521091040
   PubMed Web of Science ®Google Scholar
• Harker LA, Boissel JP, Pilgrim AJ, Gent M. Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE steering committee and investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf. 1999;21(4):325–335. doi:10.2165/00002018-199921040-0000710514023
   PubMed Web of Science ®Google Scholar
• Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol. 2000;35(5):464–469. doi:10.1080/00365520075002370510868447
   PubMed Web of Science ®Google Scholar
• Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(10):2937–2944. doi:10.1681/ASN.200604036816988059
   PubMed Web of Science ®Google Scholar
• Zhang LX, Zuo L, Xu GB, et al. Community-based screening for chronic kidney disease among populations older than 40 years in Beijing. Nephrol Dial Transplant. 2007;22(4):1093–1099. doi:10.1093/ndt/gfl76317210584
   PubMed Web of Science ®Google Scholar
• Sogabe M, Okahisa T, Nakasono M, et al. Investigation of gastroduodenal mucosal injury in Japanese asymptomatic antiplatelet drug users. Medicine. 2015;94(26):e1047. doi:10.1097/MD.000000000000104726131815
   PubMed Web of Science ®Google Scholar
• Soghomonyan S, Abdel-Rasoul M, Zuleta-Alarcon A, et al. Clopidogrel IBS patients have higher incidence of gastrointestinal symptoms influenced by age and gender. Dig Dis Sci. 2017;62(10):2728–2743. doi:10.1007/s10620-017-4707-728840395
   PubMed Web of Science ®Google Scholar
• Gentilomo C, Huang YS, Raffini L. Significant increase in clopidogrel use across U.S. children’s hospitals. Pediatr Cardiol. 2011;32(2):167–175. doi:10.1007/s00246-010-9836-021132568
   PubMed Web of Science ®Google Scholar
• Anderson RA, Bundhoo S, James PE. A new mechanism of action of thienopyridine antiplatelet drugs a role for gastric nitrosthiol metabolism? Atherosclerosis. 2014;237(1):369–373. doi:10.1016/j.atherosclerosis.2014.08.04525443875
   PubMed Web of Science ®Google Scholar
• Sambu N, Warner T, Curzen N. Clopidogrel withdrawal: is there a “rebound” phenomenon? Thromb Haemost. 2011;105(2):211–220. doi:10.1160/TH10-08-055421103667
   PubMed Web of Science ®Google Scholar
• Grove EL, Würtz M, Schwarz P, Jørgensen NR, Vestergaard P. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med. 2013;28(2):216–222. doi:10.1007/s11606-012-2208-022948933
   PubMed Web of Science ®Google Scholar
• Whittemore JC, Mooney AP, Price JM, Thomason J. Clinical, clinicopathologic, and gastrointestinal changes from administration of clopidogrel, prednisone, or combination in healthy dogs: a double-blind randomized trial. J Vet Intern Med. 2019;33(6):2618–2627. doi:10.1111/jvim.1563031593364
   PubMed Web of Science ®Google Scholar
• Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case–control study. BMJ. 2006;333(7571):726. doi:10.1136/bmj.38947.697558.AE16984924
   PubMed Web of Science ®Google Scholar
• García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123(10):1108–1115. doi:10.1161/CIRCULATIONAHA.110.97300821357821
   PubMed Web of Science ®Google Scholar
• Lim JH, Kim SG, Choi J, Im JP, Kim JS, Jung HC. Risk factors of delayed ulcer healing after gastric endoscopic submucosal dissection. Surg Endosc. 2015;29(12):3666–3673. doi:10.1007/s00464-015-4123-z25740642
   PubMed Web of Science ®Google Scholar
• Zhong HJ, Yuan Y, Xie WR, Chen MH, He XX. Type 2 diabetes mellitus is associated with more serious small intestinal mucosal injuries. PLoS One. 2016;11(9):e0162354. doi:10.1371/journal.pone.016235427598308
   PubMed Web of Science ®Google Scholar
• Harsch IA, Brzozowski T, Bazela K, et al. Impaired gastric ulcer healing in diabetic rats: role of heat shock protein, growth factors, prostaglandins and proinflammatory cytokines. Eur J Pharmacol. 2003;481(23):249–260. doi:10.1016/j.ejphar.2003.09.01914642793
   PubMed Web of Science ®Google Scholar
• Naito Y, Takagi T, Oya-Ito T, et al. Impaired gastric ulcer healing in diabetic mice: role of methylglyoxal. J Physiol Pharmacol. 2009;60(Suppl 7):123–130.
   Google Scholar
• Takagi T, Naito Y, Oya-Ito T, Yoshikawa T. The role of methylglyoxal-modified proteins in gastric ulcer healing. Curr Med Chem. 2012;19(1):137–144. doi:10.2174/09298671280341397122300087
   PubMed Web of Science ®Google Scholar
• Tariq M, Khan HA, Elfaki I, et al. Gastric antisecretory and antiulcer effects of simvastatin in rats. J Gastroenterol Hepatol. 2007;22(12):2316–2323. doi:10.1111/j.1440-1746.2007.05021.x17593225
   PubMed Web of Science ®Google Scholar
• Duan L, Bai YY, Li M, Li H, Li Y, Liu H. Increased risk of aspirin-induced gastric mucosal erosion in elderly Chinese men harboring SLCO1B1*1b/*1b while using aspirin and an ACEI or ARB concomitantly. BMC Med Genet. 2019;20(1):183. doi:10.1186/s12881-019-0918-431727004
   PubMed Web of Science ®Google Scholar
• Galeazzi R, Olivieri F, Spazzafumo L, et al. Clustering of ABCB1 and CYP2C19 genetic variants predicts risk of major bleeding and thrombotic events in elderly patients with acute coronary syndrome receiving dual antiplatelet therapy with aspirin and clopidogrel. Drugs Aging. 2018;35(7):649–656. doi:10.1007/s40266-018-0555-129936693
   PubMed Web of Science ®Google Scholar
• Yun UJ, Lee JH, Koo KH, et al. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Biochem Pharmacol. 2013;85(10):1441–1453. doi:10.1016/j.bcp.2013.02.02523473805
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360(4):363–375. doi:10.1056/NEJMoa080822719106083
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD, et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010;376(9749):1312–1319. doi:10.1016/S0140-6736(10)61273-120801494
   PubMed Web of Science ®Google Scholar
• Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749):1320–1328. doi:10.1016/S0140-6736(10)61274-320801498
   PubMed Web of Science ®Google Scholar
• Zhang JH, Tang XF, Zhang Y, et al. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. Thromb Res. 2014;134(5):970–975. doi:10.1016/j.thromres.2014.08.01725217066
   PubMed Web of Science ®Google Scholar
• Jaitner J, Morath T, Byrne RA, et al. No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting. Circ Cardiovasc Interv. 2012;5(1):82–8, S12. doi:10.1161/CIRCINTERVENTIONS.111.96540022298798
   PubMed Web of Science ®Google Scholar
• Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics. 2005;15(10):693–704. doi:10.1097/01.fpc.0000175600.26893.fa16141795
   PubMed Web of Science ®Google Scholar
• Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science. 2007;315(5811):525–528. doi:10.1126/science.113530817185560
   PubMed Web of Science ®Google Scholar
• Luo JC, Huo TI, Hou MC, et al. Clopidogrel delays gastric ulcer healing in rats. Eur J Pharmacol. 2012;695(13):112–119. doi:10.1016/j.ejphar.2012.07.05422975710
   PubMed Web of Science ®Google Scholar
• Luo JC, Peng YL, Chen TS, et al. Clopidogrel inhibits angiogenesis of gastric ulcer healing via downregulation of vascular endothelial growth factor receptor 2. J Formos Med Assoc. 2016;115(9):764–772. doi:10.1016/j.jfma.2015.07.02226315480
   PubMed Web of Science ®Google Scholar
• Wu HL, Gao X, Jiang ZD, et al. Attenuated expression of the tight junction proteins is involved in clopidogrel-induced gastric injury through p38 MAPK activation. Toxicology. 2013;304:41–48. doi:10.1016/j.tox.2012.11.02023220562
   PubMed Web of Science ®Google Scholar
• Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther. 2003;18(4):443–449. doi:10.1046/j.1365-2036.2003.01693.x12940930
   PubMed Web of Science ®Google Scholar
• Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med. 2005;352(3):238–244. doi:10.1056/NEJMoa04208715659723
   PubMed Web of Science ®Google Scholar